Also known as: Rogaine
Minoxidil is a medication used for high blood pressure and hair loss, with oral and topical forms in clinical use. It acts through potassium channel opening and vasodilatory effects, and also promotes hair growth in androgenetic alopecia. Its oral antihypertensive use was introduced in 1979, followed by topical approval for hair loss in 1988.
Veradermics will host an April 27, 2026 investor call to review topline results from Part A of its Phase 2/3 '302' trial of VDPHL01 in males with pattern hair loss. VDPHL01 is an investigational extended-release oral minoxidil tablet in Phase 3 development.
GLP-1 drugs discovered accidentally in anglerfish research now treat conditions beyond diabetes including kidney disease, sleep apnea, and addiction. The global diabetes therapeutics market is projected to reach $241.5 billion by 2030, growing at 12.4% annually.
Pharmaceutical companies are developing innovative hair loss treatments that directly activate hair growth pathways rather than suppressing male hormones, with several candidates entering clinical trials and promising enhanced safety profiles.
Oncology specialists are warning cancer patients against biotin supplementation, citing its capacity to distort critical laboratory test results including hormone panels used to monitor treatment and detect recurrence.
KilgourMD announced phase II clinical trial results showing 53% of menopausal women with hair loss achieved meaningful regrowth within four months, with a 60% reduction in hair shedding.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07594678 |
Minoxidil With or Without Low-Level Red-Light Therapy for Improving Chemotherapy-Induced Alopecia in Breast Cancer Patients |
NOT_YET_RECRUITING | PHASE2 |
| NCT07273799 |
Comparison of Outcomes Between Topical Minoxidil Versus Oral Minoxidil for the Treatment of Androgenetic Alopecia |
NOT_YET_RECRUITING | PHASE3 |
| NCT07264790 |
Assessment of Topical Minoxidil on Intraoperative Flap Perfusion and Cutaneous Flap Viability in Breast Recon |
RECRUITING | PHASE1 |
| NCT06924632 |
Efficacy & Safety of Minoxidil SL Tablets in Men With AGA |
COMPLETED | PHASE3 |
| NCT05990400 |
Effectiveness and Safety of Topical Finasteride and Minoxidil Combination Compared to Topical Minoxidil for The Treatment of Male Androgenetic Alopecia |
UNKNOWN | PHASE2/PHASE3 |
| NCT05864885 |
Phase I Study of Safety and Pharmacokinetics of Topical Solution in Subjects With Androgenetic Alopecia |
UNKNOWN | PHASE1 |
| NCT05417308 |
Topical or Oral Minoxidil for the Treatment of Endocrine Therapy-Induced Alopecia in Patients With Stage I-IV Breast Cancer |
RECRUITING | EARLY_PHASE1 |
| NCT05272462 |
Oral Minoxidil for the Treatment of Recurrent Platinum Resistant Epithelial Ovarian Cancer |
RECRUITING | PHASE2 |
| NCT04293822 |
Topical Cetirizine 1% vs Minoxidil 5% Gel in Treatment of Androgenetic Alopecia |
UNKNOWN | PHASE4 |
| NCT04207931 |
Treatment Results for Patients With Central Centrifugal Cicatricial Alopecia (CCCA): a Multicenter Prospective Study |
RECRUITING | PHASE4 |
